|By PR Newswire||
|February 25, 2014 07:00 AM EST|
OMER, Israel, Feb. 25, 2014 /PRNewswire/ -- Medigus Ltd. (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and procedures, announced today that Chris Rowland CEO, will present at the 26th Annual ROTH Conference at 2:30 p.m. PT, on March 11, 2014 in Track 6: Salon 6. The conference will be held on March 9-12, 2014 at the Ritz Carlton, 1 Ritz Carlton Drive, Dana Point, California.
A live webcast of the presentation will be available to the public at: http://wsw.com/webcast/roth28/mdgs.ta. The webcast will be archived for 90 days following the live presentation. Medigus management will be available during the day on March 11 for one-on-one meetings. Please contact your ROTH representative to schedule a meeting.
About the 26th Annual ROTH Conference
This annual conference, one of the largest of its kind in the U.S., brings together executives from hundreds of growth companies. This event is designed to provide investors with a unique opportunity to gain insight into emerging growth companies across a variety of sectors, including cleantech, consumer & retail, energy & industrial, enterprise software, healthcare, resources, semiconductors & electronics, services, and technology & media. ROTH combines company presentations, Q&A sessions, expert panels and management one-on-one meetings to provide institutional clients with extensive interaction with senior management to gain in-depth insights into each company.
Medigus is leading the transition from invasive gastric surgery procedures to less invasive, patient-friendly techniques through the development of minimally invasive endoscopic devices and procedures. The company's revolutionary MUSE™ system enables endoscopists to treat gastroesophageal reflux disease (GERD), a chronic disease with increasing global prevalence, by performing a fundoplication procedure through the mouth. Unlike current fundoplication procedures, the MUSE™ system does not require abdominal incisions, which may result in shorter post-procedure recovery. The MUSE™ endoscopy system has received FDA clearance and CE mark. Medigus is traded on the TASE (Tel Aviv Stock Exchange). To learn more about the company's minimally invasive technology platform, please visit http://www.medigus.com/.
INVESTOR RELATIONS CONTACT:
SOURCE Medigus Ltd.